Interim Report - January-September 2025
STOCKHOLM - 14 November 2025. Karolinska Development AB ( Nasdaq Stockholm: KDEV ) today publishes its Interim Report January-September 2025. The full report is available on the Company's website.
Organon Analysts Cut Their Forecasts Following Q3 Results - Organon ( NYSE:OGN )
Organon ( NYSE:OGN ) reported better-than-expected earnings for the third quarter on Monday. The company posted third-quarter adjusted earnings of $1.01 per share on Monday, beating the consensus estimate of 94 cents.
Organon Cuts 2025 Sales Outlook Despite Earnings Beat - Organon ( NYSE:OGN )
Organon ( NYSE:OGN ) reported third-quarter adjusted earnings of $1.01 per share on Monday, beating the consensus estimate of 94 cents. The global healthcare company reported quarterly sales of $1.602 billion, beating the Wall Street estimate of $1.56 billion.
Organon ( OGN ) Q3 Earnings and Revenues Beat Estimates
Organon (OGN) delivered earnings and revenue surprises of +8.60% and +2.02%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Organon & Co. ( OGN ) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman - Organon ( NYSE:OGN )
SAN FRANCISCO, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- On October 27, 2025, investors in Organon & Co. ( NYSE:OGN ) saw the price of their shares plummet $2.10 ( -23% ) after the company announced the findings of its Audit Committee's investigation into improper wholesale sales practices for ...
Gold Falls 3%; Carter's Shares Gain After Q3 Earnings - BIO-key International ( NASDAQ:BKYI ) , Co-Diagnostics ( NASDAQ:CODX )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday. The Dow traded up 0.51% to 47,449.22 while the NASDAQ rose 1.68% to 23,593.80. The S&P 500 also rose, gaining, 1.01% to 6,860.11. Communication services shares jumped by 1.5% on ...
Organon ( OGN ) Laps the Stock Market: Here's Why
The latest trading day saw Organon (OGN) settling at $9.05, representing a +1.23% change from its previous close.
Organon ( OGN ) Earnings Expected to Grow: Should You Buy?
Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Organon & Co. ( OGN ) Is a Trending Stock: Facts to Know Before Betting on It
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon ( OGN ) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Organon (OGN) closed at $9.28, marking a -1.07% move from the previous day.
Organon ( OGN ) Dips More Than Broader Market: What You Should Know
In the most recent trading session, Organon (OGN) closed at $9.38, indicating a -1.78% shift from the previous trading day.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Investors Heavily Search Organon & Co. ( OGN ) : Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon ( OGN ) Stock Slides as Market Rises: Facts to Know Before You Trade
Organon (OGN) reached $10.84 at the closing of the latest trading day, reflecting a -1.54% change compared to its last close.
Will Organon ( OGN ) Beat Estimates Again in Its Next Earnings Report?
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Organon ( OGN ) Outperforms Broader Market: What You Need to Know
Organon (OGN) reached $10.35 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.
Here's Why Organon ( OGN ) Fell More Than Broader Market
Organon (OGN) closed the most recent trading day at $10.12, moving 2.79% from the previous trading session.
Here is What to Know Beyond Why Organon & Co. ( OGN ) is a Trending Stock
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
Engagement Will Expand Daré's Engagement in Advancing Women's Health Innovation and Provide Insights into One of the Most Significant Unmet Needs in Maternal Care Engagement Will Expand Daré's Engagement in Advancing Women's Health Innovation and Provide Insights into One of the Most Significant ...
Organon ( OGN ) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Organon (OGN) stood at $10.45, denoting a -3.69% move from the preceding trading day.
Women's Health Collective Canada Launches Vital Talks National Seminar Series with the Support of Vichy Laboratoires
TORONTO, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Women's Health Collective Canada ( WHCC ) is proud to announce the launch of Vital Talks, a new national online seminar series bringing together leading researchers, clinicians, and voices with lived experience to spotlight the science shaping better ...
Organon & Co. ( OGN ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon ( OGN ) Stock Declines While Market Improves: Some Information for Investors
Organon (OGN) concluded the recent trading session at $10.26, signifying a -1.06% move from its prior day's close.
Interim Report - January-June 2025
STOCKHOLM - 29 August 2025. Karolinska Development AB ( Nasdaq Stockholm: KDEV ) today publishes its Interim Report January-June 2025. The full report is available on the Company's website.
Organon & Co. ( OGN ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Daré Bioscience Posts Narrower Q2 Loss
Daré Bioscience ( NASDAQ:DARE ) , a women's health-focused biopharmaceutical company developing new therapies and devices, announced its second quarter 2025 results on August 14, 2025. The headline news was a negative GAAP revenue figure of $21,172, falling far short of the $280,000 consensus ...
Investors Heavily Search Organon & Co. ( OGN ) : Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
OGN vs. HQY: Which Stock Is the Better Value Option?
Investors interested in Medical Services stocks are likely familiar with Organon ( OGN Quick QuoteOGN - ) and HealthEquity ( HQY Quick QuoteHQY - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Organon ( OGN ) Fiscal Q2 Revenue Beats 1%
Organon ( NYSE:OGN ) , a pharmaceutical company focused on women's health, biosimilars, and established brands, released its fiscal Q2 2025 ( ended June 30, 2025 ) results on August 5, 2025. The company reported GAAP revenue of $1.59 billion, above analyst expectations of $1.552 billion, and ...
Organon ( OGN ) Beats Q2 Earnings and Revenue Estimates
Organon (OGN) delivered earnings and revenue surprises of +6.38% and +2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Insights Into Organon ( OGN ) Q2: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Organon (OGN) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Organon ( OGN ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Organon (OGN) closed at $9.7, indicating a -3.39% shift from the previous trading day.
Cencora ( COR ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon ( OGN ) Expected to Beat Earnings Estimates: Should You Buy?
Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most ...
Organon ( OGN ) Outperforms Broader Market: What You Need to Know
In the latest trading session, Organon (OGN) closed at $10.21, marking a +1.39% move from the previous day.
Here is What to Know Beyond Why Organon & Co. ( OGN ) is a Trending Stock
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses. July 22, 2025 Deadline to file Lead Plaintiff Motion - Organon ( NYSE:OGN )
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 22, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Organon & Co. ( "Organon" or the "Company" ) OGN investors of a class action representing investors that bought securities ...
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
The Gross Law Firm Notifies Organon & Co. Investors of a Class Action Lawsuit and Upcoming Deadline - OGN - Organon ( NYSE:OGN )
NEW YORK, July 21, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. OGN. Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
A first-of-its-kind solution for women's arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most ...
OGN or MEDP: Which Is the Better Value Stock Right Now?
OGN vs. MEDP: Which Stock Is the Better Value Option?
INVESTOR DEADLINE TOMORROW: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - OGN - Organon ( NYSE:OGN )
SAN DIEGO, July 21, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Organon & Co. OGN publicly traded securities between November 3, 2022 and April 30, 2025, inclusive ( the "Class ...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon - Organon ( NYSE:OGN )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options
ORGANON DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. ( OGN ) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit - Organon ( NYSE:OGN )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Organon ( OGN ) To Contact Him Directly To Discuss Their Options
Organon ( OGN ) Registers a Bigger Fall Than the Market: Important Facts to Note
Organon (OGN) closed at $9.46 in the latest trading session, marking a -1.87% move from the prior day.
Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses; July 22, 2025 Deadline to file Lead Plaintiff Motion - Organon ( NYSE:OGN )
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 18, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Organon & Co. ( "Organon" or the "Company" ) OGN investors of a class action representing investors that bought securities ...
